The material provided in this site is presented solely to improve public access to information about REVANCE. REVANCE will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. REVANCE will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site. REVANCE may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of REVANCE and affiliates to be materially different from those expected or anticipated in the forward-looking statements. REVANCE has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.
Links to third-party sites
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by REVANCE. The linked sites are not under control of REVANCE, and REVANCE disclaims any liability for all third party information and the use of it.
Restrictions on use and submissions
The contents of this site are owned and controlled by REVANCE. No use of any of these may be made without the prior written consent of REVANCE, except for personal, non-commercial purposes. All submissions communicated to REVANCE through this site shall be and remain REVANCE’s property.
The glabella is the skin that sits between the eyebrows and above the nose. Facial wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors.
Revance will initially address one of the largest demands within the facial aesthetics category, glabellar (frown) lines.
Revance Clinical Program Update:
Product candidate DaxibotulinumtoxinA For Injection (DAXI) has been evaluated in a Phase 2 head-to-head, active comparator study (BELMONT), and in three Phase 3 trials (SAKURA), for the treatment of glabellar lines. The company plans to file for regulatory approval in the Fall of 2019 and potentially launch DAXI in 2020.
DAXI is also being studied for the treatment of forehead line and lateral canthal lines (crow's feet). Phase 2 trials are expected to be fully enrolled in the Summer of 2019 and have results in the first half of 2020. These studies will provide valuable dosing and injection site information on DAXI's potential use across the upper face.
For the latest information regarding our clinical development programs, please see our public filings with the Securities and Exchange Commissions, as well as the press releases we issue, or visit www.clinicaltrials.gov
Anti-Aging: Facts, Figures & Trends
Use of botulinum toxin products for aesthetic and therapeutic indications represents an estimated $4.5 billion market globally.
Botulinum toxin procedures continue to drive the nonsurgical aesthetic market and have remained the #1 nonsurgical procedure since 2000.
Botulinum toxin injections (aesthetic) have seen a 5,407% increase in number of procedures from 1997-2014.*
A recent quantitative study of 80 community dermatologists and cosmetic surgeons revealed that DAXI, if approved, would address an unmet need by offering a longer duration of effect. This same group voiced a significant likelihood to use DAXI and make it their treatment of choice.**
* 2015 ASAPS Statistical data
** Revance. Data on file.
The glabella is the skin that sits between the eyebrows and above the nose.
Facial wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors.
Aging theory suggests that wrinkles develop from incorrect repairs of injured elastic fibers and collagen fibers. Repeated extensions and compressions of the skin cause repeated injuries of extracellular fibers in derma. During the repairing process, some of the broken elastic fibers and collagen fibers are not regenerated and restored, but replaced by altered fibers.
Botulinum toxin treats glabellar (frown) lines by immobilizing the muscles that cause wrinkles.
Facts, Figures & Trends
Deep muscles like those that form the glabellar (frown) lines may be best served by an injectable formulation like DAXI.